FDA

News

Vanda slams FDA rejection of gastroparesis drug

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company.

News

AbbVie faulted for misleading ad featuring Serena Williams

Pharma giant AbbVie has been taken to task by the FDA for running an ad for one of its migraine drugs, featuring tennis star Serena Williams, which the agency says overstates its efficacy.<

News

PBC drug choices rise in US with OK for Gilead's seladelpar

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade.

News

Article retractions muddy MDMA waters after FDA denial

The journal Psychopharmacology has retracted three articles about MDMA-assisted psychotherapy, shortly after the FDA rejected approval of Lykos Therapeutics' therapy for post-traumatic stre

News

FDA clears first anaphylaxis nasal spray at second attempt

ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first needle-free alternative to EpiPen-style autoinjectors for serious allergic reactions.

News

FDA shoots down Lykos' MDMA therapy for PTSD

The FDA has denied Lykos Therapeutics' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psyche

Vanda slams FDA rejection of gastroparesis drug

AbbVie faulted for misleading ad featuring Serena Williams

PBC drug choices rise in US with OK for Gilead's seladelpar

Article retractions muddy MDMA waters after FDA denial

FDA clears first anaphylaxis nasal spray at second attempt

FDA shoots down Lykos' MDMA therapy for PTSD

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks